Replies to post #198563 on Avid Bioservices Inc (CDMO)

[biopharm]

Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL : Video =48:53 in length ....

...must sign up for free trial to see the entire video and yes, its very relevant to Peregrine and PS Targeting, since PS Targeting is the core action that ultimately provides that optimal immune response. The days of Big Pharma getting drugs approved blindly by saying "Oh.. the tumor stopped growing" are just about over. I think "mostly" toxic chemo would cause just about anything in its path to come to a halt, good cells and bad.

Now comes Immunotherapy or I/O Immuno Oncology and all the immuno suppressive qualities that were related with MDSC's has been known since the 1970's if you watch the video and why has Big Pharma not changed their research up till now ???

Change is coming and it could not come soon enough

TOPICS COVERED IN THIS TALK


Myeloid derived suppressor cells (MDSC) and their potent immune suppressive activity

MDSC in cancer

MDSC in chronic infections

MDSC during stress

MDSC in surgical trauma

The two main populations of MDSC: monocytic MDSC (M-MDSC) and polymorphonuclear MDSC (PMN-MDSC)

Biological differences between MDSC and their normal counterparts

Multiple mechanisms of expansion regulation and immune suppressive function of MDSC

MDSC role in antigen-specific T cell tolerance in tumor-bearing mice

Therapeutic regulation of MDSC in mice and humans

------------

DETAILED SLIDE INDEX

1. Introduction
2. Talk outline
3. Brief history of MDSC
4. Overview on MDSC
5. Immune tolerance and suppression
6. MDSC in tumor vs. peripheral lymphoid organs
7. Accumulation of MDSC in tumor models
8. Immature myeloid cells in tumor-bearing host
9. MDSC in lymph nodes
10. Subsets of myeloid-derived suppressor cells
11. Differentiating two subsets of MDSC
12. PMN-MDSC (main subset of suppressor cells)
13. PMN-MDSC can derive from M-MDSC
14. PMN-MDSC in cancer
15. T cell suppressive activity: Lin-HLA-DR-CD33+
16. T cell suppressive activity: CD14-CD11b+CD33+
17. Mechanisms regulating MDSC expansion
18. Potential models of MDSC accumulation
19. Signaling pathways involved in MDSC expansion
20. Signaling pathways involved in MDSC activation
21. Hyperactivation of JAK2 and STAT-3 in MDSC
22. The STAT-3 axis involved in MDSC regulation
23. Mechanisms of MDSC activity
24. Mechanisms of immune suppression by MDSC
25. Immune suppression and MDSC sub-populations
26. MDSC-induced CD8+ T cell tolerance
27. Main mechanism of T cell tolerance
28. MDSC cause nitration of TCR on CD8+ T cells
29. MDSC interaction with CD8+ T cells
30. How MDSC cause T cell tolerance
31. Expression of MHC class I and class II on MDSC
32. Antigen-specific suppression & MHC class II
33. MDSC from MC38 mice cause tolerance
34. MDSC-inducible T cell tolerance & MHC class II
35. Antigen-specific CD4+ T cells convert MDSC
36. Direct cell-cell contact is needed for conversion
37. Absence of the antigen & conversion failure
38. Cross-linking of MHC class II & MDSC conversion
39. Expression due to cross-linking of MHC class II
40. Inhibition of COX2 blocked effect of cross-linking
41. Inhibition of COX2 in vivo
42. Interaction of MDSC with CD4+ T cells
43. MDSC effect in peripheral lymphoid organs
44. Interaction of MDSC with CD4+ T cell subsets
45. MDSC effect on tumor progression
46. MDSC migration to the tumor site
47. Tumor metastases and subsets of MDSC
48. Therapeutic targeting of MDSC in cancer
49. Overview of therapeutic agents
50. Summary
51. Acknowledgments
52. END


http://hstalks.com/main/view_talk.php?t=2956&r=494&j=755&c=252